Overall, our results provide evidence that upregulated SALL4 can function as a crucial regulator of tumor pathogenesis and progression in ccRCC, thus offering potential therapeutic strategies for future treatment. Here, SALL4 is linked to nonpapillary renal cell carcinoma.